BDBM426414 (2-(2H-1,2,3-triazol-2-yl)phenyl)((2R,5R)-5-((3-bromoimidazo[1,2-a]pyrazin-8-yl)oxy)-2-methylpiperidin-1-yl)methanone::US10526336, Example 33::US10526336, Example 41::US10526336, Example 57

SMILES C[C@@H]1CC[C@H](CN1C(=O)c1ccccc1-n1nccn1)Oc1nccn2c(Br)cnc12

InChI Key InChIKey=HXEUUKAITDSZMK-UHFFFAOYSA-N

Data  6 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 6 hits for monomerid = 426414   

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426414(US10526336, Example 33 | US10526336, Example 41 | ...)
Affinity DataIC50: 8.90nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426414(US10526336, Example 33 | US10526336, Example 41 | ...)
Affinity DataIC50: 13.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426414(US10526336, Example 33 | US10526336, Example 41 | ...)
Affinity DataIC50: 45.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426414(US10526336, Example 33 | US10526336, Example 41 | ...)
Affinity DataIC50: 1.20E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426414(US10526336, Example 33 | US10526336, Example 41 | ...)
Affinity DataIC50: 1.51E+3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin/Hypocretin receptor type 1(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426414(US10526336, Example 33 | US10526336, Example 41 | ...)
Affinity DataIC50: 1.00E+4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent